AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33000618
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 deficiency (<20 ng/mL)
Trial: 34049919
Drug: Other immunosuppressants
RxNorm normalized name: Other immunosuppressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other immunosuppressants (including mycophenolate mofetil)
Trial: 34049919
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment specified
Trial: 33663487
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) and sulfasalazine (SSZ) for the first 12 weeks, then remove TNFi but continue other treatments for the next 48 weeks.
Trial: 33663487
Drug: Maintain TNFi
RxNorm normalized name: mountain pepper whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain TNFi + MTX for the first 12 weeks, then remove TNFi but continue MTX monotherapy for the next 48 weeks.
Trial: 33663487
Drug: Incremental cost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, CDAI, and SDAI; the proportion of modified Sharp score increase < 0.3; ultrasound-detected remission in hands; Health Assessment Questionnaire Disability Index (HAQ-DI); health-related quality of life (EQ-5D-5L and SF-6D).
Trial: 32068484
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg vibegron
Trial: 32068484
Drug: Extended-release 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release 4 mg tolterodine
Trial: 36227170
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PMT and CPS)
Trial: 33097351
Drug: Diazepam 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.1 mg/kg plus fentanyl 1 μg/kg IV
Trial: 33097351
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg/kg plus fentanyl 1 μg/kg IV
Trial: 35101115
Drug: Monthly (28-day)
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly (28-day) INJ-BUP
Trial: 35101115
Drug: Daily SL-BUP/NLX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SL-BUP/NLX
Trial: 35436231
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics
Trial: 32881968
Drug: ALFA-adjuvanted vaccine
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALFA-adjuvanted vaccine
Trial: 39083587
Drug: Alum-adjuvanted vaccine
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted vaccine
Trial: 32007099
Drug: Model-based PEEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-based PEEP titration
Trial: 32035487
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg every 2 weeks (Q2W) with possible increase to 150 mg Q2W at Week 12
Trial: 32035487
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (ezetimibe, fenofibrate, or no additional lipid-lowering therapy)
Trial: 35426822
Drug: Gelfoam carrier
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelfoam carrier soaked in 1 ml of triamcinolone acetonide (40 mg)
Trial: 34445031
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula containing 5HMO-Mix (5.75 g/L total, comprising 52% 2′‐fucosyllactose, 13% 3‐fucosyllactose, 26% lacto‐N‐tetraose, 4% 3′‐sialyllactose, and 5% 6′‐sialyllactose)
Trial: 36323130
Drug: Zonisamide 25
RxNorm normalized name: zonisamide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 25 mg add-on
Trial: 35565903
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera (MO) dry leaf powder, 6 × 400 mg capsules/day for 12 weeks
Trial: 33001135
Drug: Nivolumab 1
RxNorm normalized name: nivolumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (arm A)
Trial: 33001135
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (arm B)
Trial: 33001135
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C)
Trial: 32358807
Drug: Inhaled dry
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dry powder mannitol
Trial: 35852013
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ca (OH)2 and Allium sativum
Trial: 32267348
Drug: Vildagliptin added
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin added to insulin therapy
Trial: 32267348
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued insulin therapy)
Trial: 37352880
Drug: Inactivated vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated vaccine
Trial: 32843496
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus coronary artery bypass graft surgery (CABG)
Trial: 32955088
Drug: RZF 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZF 400 mg QWk
Trial: 32955088
Drug: RZF 400/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RZF 400/200 mg QWk
Trial: 32955088
Drug: CAS 70
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS 70 mg loading dose followed by 50 mg daily for ≤4 weeks
Trial: 35968303
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication use
Trial: 38547892
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events
Trial: 32586434
Drug: Be a
RxNorm normalized name: Tube Attaching Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Be a Mom (self-guided web-based intervention grounded in cognitive behavioral therapy)
Trial: 35645331
Drug: Nurse-led Adverse
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led Adverse Drug Reaction (ADRe) Profile
Trial: 34869486
Drug: Hydroxybutyl chitosan
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxybutyl chitosan (HBC) injection
Trial: 33885930
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA treatment for 24 weeks
Trial: 33126317
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents (ESAs) combined with traditional Chinese medicine (TCM)
Trial: 39581908
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents (ESAs)
Trial: 36416492
Drug: Psilocybin (0.143
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (0.143 mg/kg)
Trial: 32332672
Drug: Continuous adductor
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous adductor canal block (CACB) with 0.5% ropivacaine 20 mL followed by continuous infusion of 0.2% ropivacaine at 5 mL/h for 48 hours
Trial: 32332672
Drug: Single‐injection adductor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐injection adductor canal block (SACB) with 0.5% ropivacaine 20 mL
Trial: 32332672
Drug: Single‐injection adductor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single‐injection adductor canal block (SACB)
Trial: 34003071
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg capsule, 1 hour before)
Trial: 34003071
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose capsule, 1 hour before)
Trial: 37941802
Drug: 10-µg/dose vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-µg/dose vaccine
Trial: 37941802
Drug: 5-µg/dose vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-µg/dose vaccine
Trial: 32955164
Drug: 20 IU·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU·kg bw−1 rhEpo injections every second day for 3 weeks during exposure at sea level
Trial: 32955164
Drug: 20 IU·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU·kg bw−1 rhEpo injections every second day for 3 weeks during exposure at altitude
Trial: 32955164
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections at sea level
Trial: 32955164
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections at altitude
Trial: 36251544
Drug: Treatment groups
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment groups (SDF, SDF-KI, RV-SDF, RV-SDFKI)
Trial: 34405256
Drug: 6-day subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-day subcutaneous GIP infusion (6 pmol kg-1 min-1)
Trial: 34405256
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline [154 mmol/l NaCl])
Trial: 32998143
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg monotherapy
Trial: 34954841
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg 2 ml autoinjector (AI)
Trial: 34954841
Drug: Secukinumab 2×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 2× 1 ml prefilled syringe (PFS)
Trial: 34954841
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg 2 ml AI
Trial: 35306231
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) after multiagent chemotherapy (MA‐CTX)
Trial: 32813947
Drug: Evinacumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evinacumab (15 mg/kg every 4 weeks)
Trial: 35354325
Drug: Pharmacotherapy treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy treatments
Trial: 35465275
Drug: Cefazolin 2
RxNorm normalized name: cefazolin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 2 g 30-60 min before incision (Group A)
Trial: 35465275
Drug: Cefazolin 2
RxNorm normalized name: cefazolin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 2 g 30-60 min before incision and Tinidazole 1.6 g 60-120 min before incision (Group B)
Trial: 34106582
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural play therapy (CBPT)
Trial: 36339275
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of omega-3 fatty acids and inositol
Trial: 35324094
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 50‐300 mg/d
Trial: 35838110
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clavulanate potassium suspension (200 mg/28.5 mg) under fasting conditions
Trial: 35838110
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clavulanate potassium suspension (200 mg/28.5 mg) under postprandial conditions
Trial: 33580923
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost 0.005% ophthalmic solution
Trial: 33580923
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone diproprionate 0.05% lotion
Trial: 35262625
Drug: Prasugrel dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel dose de-escalation (5 mg daily) at 1 month post-PCI
Trial: 35262625
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (10 mg daily)
Trial: 34997899
Drug: Internet-Delivered Acceptance
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-Delivered Acceptance and Commitment Therapy (iACT)
Trial: 32202510
Drug: PI-mono (ritonavir-boosted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-mono (ritonavir-boosted protease inhibitors)
Trial: 35318869
Drug: Crisis Counselling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisis Counselling (CC)
Trial: 34405305
Drug: Opioid antagonist
RxNorm normalized name: OPIOID ANTAGONIST ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid antagonist naltrexone (50 mg)
Trial: 32274491
Drug: Single low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single low level laser therapy
Trial: 34109364
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 μg/kg)
Trial: 34109364
Drug: Midazolam +
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam + Fentanyl (0.02 mg/kg midazolam and 2.0 μg/kg fentanyl)
Trial: 34242246
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor inhibitors (TNFi) in combination with MTX
Trial: 35856483
Drug: Dermapen and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermapen and topical coconut oil
Trial: 35856483
Drug: Dermapen and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermapen and topical sesame oil
Trial: 35856483
Drug: Periodontal mechanical
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periodontal mechanical treatment only
Trial: 32122703
Drug: Photobiomodulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation treatment (GaAs diode laser, continuous wave 980nm, power 100mW, energy density 12J/cm2, applied on days 1, 3, 7, 14, 21, and 28 postoperatively)
Trial: 33793678
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antiviral and nonsteroidal anti-inflammatory treatment
Trial: 36083516
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) for 48 weeks
Trial: 32040875
Drug: Atraumatic Restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic Restorative Treatment and Hall Technique (ART/HT)
Trial: 35264075
Drug: Prebiotic-rich yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic-rich yogurt (100g daily for 6 weeks)
Trial: 36450626
Drug: cobimetinib (cobi)
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: cobimetinib (cobi) 60 mg/day on days 1-21
Trial: 36450626
Drug: cobimetinib (cobi)
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: cobimetinib (cobi) 40 mg/day on days 1-21 + venetoclax (ven) 800 mg/day on days 1-28
Trial: 36450626
Drug: cobimetinib (cobi)
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: cobimetinib (cobi) 40 mg/day on days 1-21 + venetoclax (ven) 800 mg/day on days 1-28 + atezolizumab (atezo) 840 mg on days 1 and 15 of 28-day cycles
Trial: 32586153
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy with coronary angiography and optimal medical treatment
Trial: 32586153
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy with only optimal medical treatment
Trial: 32052831
Drug: Ceftriaxone 250
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days plus metronidazole for 14 days
Trial: 32052831
Drug: Ceftriaxone 250
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 250 mg intramuscular single dose and doxycycline for 14 days
Trial: 34258686
Drug: Continuous antibiotic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antibiotic infusion (CAI) via an ambulatory pump
Trial: 34258686
Drug: Standard pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pump and intermittent antibiotic administration (IAA)
Trial: 33253659
Drug: Extensive intraoperative
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extensive intraoperative peritoneal lavage (EIPL) with 1 L of warm normal 0.9% saline, repeated ten times after surgery.
Trial: 32303763
Drug: ALM 100
RxNorm normalized name: Atopalm 100 MG/ML Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALM 100 mg
Trial: 32303763
Drug: ALM 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALM 200 mg
Trial: 32303763
Drug: ZOL 10
RxNorm normalized name: danazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOL 10 mg
Trial: 35742357
Drug: Tropocollagen gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropocollagen gel treatment (group A, n = 47)
Trial: 34491449
Drug: Treatment by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by dental students
Trial: 34888663
Drug: Soluble corn
RxNorm normalized name: soluble corn fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble corn fiber (SCF) 20 g/day for 2 months
Trial: 33328324
Drug: siponimod 2
RxNorm normalized name: siponimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod 2 mg/d
Trial: 39129649
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg daily
Trial: 33922783
Drug: Caffeine loading
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine loading 40 mg/kg/day and maintenance 20 mg/kg/day
Trial: 33922783
Drug: Caffeine loading
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine loading 20 mg/kg/day and maintenance 10 mg/kg/day
Trial: 32985341
Drug: Topiramate 50
RxNorm normalized name: topiramate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 50 to 100 mg/day
Trial: 36205549
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (RW) consumption (250 mL/d, 5 d/wk for 3 weeks)
Trial: 32340155
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive training intervention with lab-based tasks, specific dosage and duration not mentioned.
Trial: 34899426
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT‐bt)
Trial: 35954975
Drug: General psychoeducation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General psychoeducation about psychological treatments for mental health
Trial: 36036731
Drug: ADD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADD group (n=15) consuming pecans (68 g) as part of a free-living diet
Trial: 36036731
Drug: SUB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUB group (n=16) substituting pecans (68 g) for isocaloric foods from their habitual diet
Trial: 35667721
Drug: Immediate initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate initiation of anti-TB therapy
Trial: 35667721
Drug: Sepsis-specific dose
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sepsis-specific dose anti-TB therapy
Trial: 33588893
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (1 g of ferric carboxymaltose) when hepcidin < 20 μg/l and intravenous iron and erythropoietin for 20 ≤ hepcidin < 41 μg/l.
Trial: 33588893
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron treatment according to hepcidin levels.
Trial: 33891907
Drug: Full-dose anticoagulation
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose anticoagulation with rivaroxaban 20 mg once daily (or full-dose heparin if oral administration is not feasible) for 30 days
Trial: 33891907
Drug: Full-dose anticoagulation
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban through 30 days